Boehringer strikes €307M col­lab­o­ra­tion deal with Mi­NA; Tri­ci­da banks $57.5M ven­ture round for PhI­II

→ Boehringer In­gel­heim and Mi­NA Ther­a­peu­tics will col­lab­o­rate on new drugs for fi­brot­ic liv­er dis­eases like NASH. Mi­NA’s been work­ing on a small ac­ti­vat­ing RNA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER